EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6OP: OSE IMMUNOTHERAPE.EO -20

07 Nov 2025
LAST:

5.300

CHANGE:
 0.11		OPEN:
5.300		HIGH:
5.300		ASK:
0.000		VOLUME:
200
CHG(%):
2.03		PREV:
5.410		LOW:
5.300		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 255.3005.3005.3005.300200
06 Nov 255.4105.4105.4105.410200
05 Nov 255.6505.6505.6505.650200
04 Nov 255.6005.6005.6005.600200
31 Oct 255.9705.9705.9705.970200
30 Oct 255.8505.8505.8505.850200
29 Oct 255.8255.8255.8255.825200
28 Oct 255.9205.9205.9205.920200
27 Oct 256.1406.1406.1406.140200
24 Oct 255.9505.9505.9505.950200

COMPANY PROFILE

Name:OSE IMMUNOTHERAPE.EO -20
About:OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Sector:Healthcare
Industry:Biotechnology
Address:22, boulevard Benoni Goulin, Nantes, France, 44200
Website:https://www.ose-immuno.com
ISIN:FR0012127173

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:4.45 
Forward P/E:2.11 
Price to Sales:1.58 
Price to Book:2.01 
Profit Margin:0.45 
Operating Margin:-22.72 
Return on Assets:0.27 
Return on Equity:0.86 
Revenue:83.44M 
EBITDA:34.64M 
Shares:22.89M 
Market Cap:121.32M 

TECHNICAL INDICATORS

MA5:5.595.4%
MA10:5.768.7%
MA20:6.0714.5%
MA50:6.0714.5%
MA100:5.819.6%
MA200:5.9912.9%
RSI14:30.10 
WPR14:-100.00 
MTM14:-0.69
ROC14:-0.12 
ATR:0.21 
Week High:5.9712.6%
Week Low:5.300.0%
Month High:6.9531.1%
Month Low:5.3012.9%
Year High:10.0289.1%
Year Low:4.7811.0%
Volatility:48.52